Ovid Therapeutics Inc.

NasdaqGS:OVID 株式レポート

時価総額:US$78.1m

Ovid Therapeutics 将来の成長

Future 基準チェック /26

Ovid Therapeuticsの収益は年間20.6%で減少すると予測されていますが、年間収益は年間45.5%で増加すると予測されています。EPS は年間 減少すると予測されています。自己資本利益率は 3 年後に-88.8% 12.9%なると予測されています。

主要情報

-20.6%

収益成長率

-12.9%

EPS成長率

Biotechs 収益成長28.3%
収益成長率45.5%
将来の株主資本利益率-88.8%
アナリストカバレッジ

Good

最終更新日26 Nov 2024

今後の成長に関する最新情報

Recent updates

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

Apr 09

We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Nov 10
We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

Jun 27
Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation

Mar 13
Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation

Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

Sep 09
Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04

Aug 09

We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully

Jun 09
We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully

Ovid Therapeutics: Good Entry Point For Investors

Jun 18

Ovid Therapeutics appoints Jeff Rona as CFO

Jun 04

Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability

Apr 16
Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability

Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts

Mar 20
Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts

Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Mar 18
Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

Mar 01
We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?

Jan 25
Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?

Revisiting Ovid Therapeutics

Jan 14

Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?

Dec 21
Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?

Ovid Therapeutics misses goal in Angelman syndrome treatment

Dec 01

業績と収益の成長予測

NasdaqGS:OVID - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/202630-29N/AN/A3
12/31/20256-43N/AN/A5
12/31/20241-34N/AN/A8
9/30/20241-33-58-58N/A
6/30/20241-30-53-53N/A
3/31/20240-51-50-50N/A
12/31/20230-52-46-46N/A
9/30/20230-49-43-43N/A
6/30/20230-49-46-46N/A
3/31/20230-51-49-47N/A
12/31/20222-54-57-55N/A
9/30/20221-68-60-58N/A
6/30/20221-66-58-56N/A
3/31/20221-67-63-62N/A
12/31/2021208120118119N/A
9/30/2021214123116116N/A
6/30/2021221117125126N/A
3/31/2021221110128128N/A
12/31/202013-81-52-52N/A
9/30/20207-76-54-54N/A
6/30/2020N/A-76-62-62N/A
3/31/2020N/A-67-57-57N/A
12/31/2019N/A-60-51-51N/A
9/30/2019N/A-56-45-45N/A
6/30/2019N/A-53-46-46N/A
3/31/2019N/A-53-46-45N/A
12/31/2018N/A-52-46-46N/A
9/30/2018N/A-50-44-44N/A
6/30/2018N/A-46N/A-43N/A
3/31/2018N/A-44N/A-37N/A
12/31/2017N/A-65N/A-31N/A
9/30/2017N/A-61N/A-28N/A
6/30/2017N/A-58N/A-23N/A
3/31/2017N/A-53N/A-21N/A
12/31/2016N/A-22N/A-18N/A
9/30/2016N/A-18N/A-14N/A
12/31/2015N/A-13N/A-5N/A

アナリストによる今後の成長予測

収入対貯蓄率: OVID今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: OVID今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: OVID今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: OVIDの収益 ( 45.5% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: OVIDの収益 ( 45.5% ) 20%よりも速いペースで成長すると予測されています。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: OVID 3 年以内に赤字になると予測されています。


成長企業の発掘